Expanding Access to Personalized Radiation Therapy for Prostate Cancer Patients Why do more than 20% of prostate cancer patients experience persistent urinary side effects after radiation therapy? MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, is…
Gossamer Bio Reports Mixed Results for Seralutinib in PAH, Demonstrates Strong Efficacy in High-Risk Subgroups Is the current landscape of pulmonary arterial hypertension (PAH) treatments failing to meet the needs of high-risk patients? Gossamer Bio, Inc. a biopharmaceutical company focused…
IDT Launches Advanced NGS Portfolio to Tackle Key Bottlenecks in Cancer Research As cancer research enters a new era defined by ultra-sensitive identification and rapidly expanding biomarker landscapes, Integrated DNA Technologies (IDT) is announcing a suite of next-generation sequencing (NGS)…
Global Healthcare Leader Organon Licenses Sebela Pharmaceuticals’ MIUDELLA for Diverse Reproductive Health Needs Why is the landscape of women’s reproductive health evolving so rapidly? Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a…
Biotech Pioneer SylamoreBio Collaborates with Daiichi Sankyo to Tackle CNS Delivery Challenges How can biotech companies overcome the formidable barriers to delivering therapies to the central nervous system (CNS)? SylamoreBio, a biotechnology company dedicated to advanced therapeutic delivery, is addressing…
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences, Inc. has made a significant move. The biopharmaceutical giant has…
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the US Food and Drug Administration…
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer bioAffinity Technologies, Inc. a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new…
BioTalent Canada Launches Training to Help Employers Prevent and Respond to Workplace Sexual Harassment BioTalent Canada is launching online training courses to empower managers and hiring leaders to confidently prevent and address workplace sexual harassment in Canada’s bio-economy. These courses…
Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma Pilatus Biosciences Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced that the U.S. Food and Drug Administration…
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026 Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American…
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for…
